Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celcuity Inc. on July 29, 2025, covering events occurring on July 28, 2025. The company is a biopharmaceutical firm focused on developing targeted therapies, currently advancing its Phase 3 VIKTORIA-1 clinical trial.
Key Financial Metrics and Liquidity
- Cash Position: Preliminary cash, cash equivalents, and short-term investments are approximately $168.4 million as of June 30, 2025.
- Debt Capacity: The company is eligible to incur an additional $30.0 million in indebtedness under the Term D Loan following the achievement of a clinical milestone.
- Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for the period.
Material Changes and Agreements
- Loan Amendment: Entered into a Second Amendment to its Amended and Restated Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP and Oxford Finance LLC. This amendment permits the issuance of convertible notes and related capped call transactions.
- Conversion Rights Extension: Extended the expiration date of Innovatus' right to convert up to 20% of the Term A Loan principal into common stock at $10.00 per share to May 9, 2026.
- Amendment Fee: Paid a $25,000 fee to Oxford Finance LLC at the closing of the amendment.
- Proposed Offering: Announced a concurrent offering to issue $150.0 million in Convertible Senior Notes due 2031 and sell $75.0 million of common stock.
Outlook, Risks, and Management Commentary
Management intends to draw down the additional $30.0 million Term D Loan in late August 2025, prior to the August 31, 2025 expiration of the draw period. The company expects to complete its interim financial statements for the three and six months ended June 30, 2025, after the proposed offering is completed. Preliminary financial data is unaudited and subject to potential adjustments.
Risks and Contingencies: Forward-looking statements are subject to risks including the potential delay or termination of the proposed offering, failure to draw the Term D Loan within the specified period, and the identification of unexpected adjustments to preliminary financial data.
Investor Verification Checklist
- Verify the final terms and closing status of the proposed $150.0 million convertible notes and $75.0 million common stock offering.
- Confirm the successful drawdown of the $30.0 million Term D Loan by August 31, 2025.
- Review the full text of the Second Amendment to the Loan Agreement (Exhibit 10.1) for detailed covenants and conditions.
- Monitor the upcoming audited interim financial statements for the period ended June 30, 2025, to confirm the $168.4 million cash position.